HAL (France)open access
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Radiotherapy, Efficacy, Guidelines, Advanced stage, Toxicity, Chemotherapy, 1, Geriatric assessment
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 333826
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.